NextCell strengthens the organization for continued growth
NextCell Pharma AB ("NextCell") hereby announces that the Board has decided to appoint Sofia Fredrikson to CFO in the company. Sofia Fredrikson will take office starting today. Former CFO, Leo Groenewegen, will continue to work for the company in the newly created role of Business Development Manager. Both Sofia Fredrikson and Leo Groenewegen will be part of NextCell's management team.
Sofia Fredrikson, born 1983, has been employed by NextCell since November 2018. The Board has now decided to appoint Fredrikson as CFO for the company. Sofia Fredrikson has worked as an authorized accountant with over 10 years of experience in accounting and auditing. Previously, Fredrikson has been employed at KPMG AB and recently at BDO AB. Leo Groenewegen has been CFO at NextCell since May 2017. In the new role of Business Development Manager, Groenewegen will focus on identifying new business opportunities for NextCell.
"NextCell has good momentum in business and an exciting journey ahead. The clinical development of ProTrans is progressing smoothly and Cellaviva has recently decided to expand to Denmark. We are currently experiencing increased public interest in our business, which requires the organization to expand. By appointing Sofia Fredrikson to CFO and Leo Groenewegen as Business Development Manager, we create space for new business opportunities and continued growth, "commented Mathias Svahn, CEO of NextCell.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 5th of December 2018.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.